Papers & Publications

  1. Thisyakorn U, Capeding MR, Goh DYT, et al. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines. 2014 May;13(5):581-587.
    Available at: http://lkyspp.nus.edu.sg/wp-content/uploads/2014/05/DengueVaccine2014ExpRevs1.pdf
     
  2. Thisyakorn U, Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014 Jan;2(1):3–9.
    Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991153/pdf/10.1177_2051013613507862.pdf
     
  3. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358-1365.
    Available at: http://www.ncbi.nlm.nih.gov/pubmed/25018116
     
  4. Thisyakorn U. ADVASC-new regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia. Vaccine. 2012 Aug 17;30(38):5587-5588.
    Available at: http://www.ncbi.nlm.nih.gov/pubmed/22709950
     
  5. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. NEJM. 2015.
    Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1506223
     
  6. Questions and Answers on Dengue Vaccines: Efficacy and longer-term safety of CYD-TDV.
    Available at: http://www.who.int/immunization/research/development/dengue_q_and_a/en/. Accessed on: 29 July 2015
     
  7. Statement by the Dengue Vaccine Initiative on the Results of CYD-TVD Phase 3 Trial in Latin America.
    Available at: http://www.denguevaccines.org/sites/default/files/DVI%20Statement%20CYD15-%20111014.docx__0.pdf. Accessed on: 29 July 2015.
     
  8. Technical consultation with national regulatory authorities on the dengue vaccine dossier.
    Available at: http://www.who.int/immunization/research/meetings_workshops/dengue_vaccdossier/en/. Accessed on: 29 July 2015.
     
  9. New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur’s Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue.
    Available at: http://www.sanofipasteur.com/en/articles/New-England-Journal-of-Medicine-Publishes-New-Analyses-Confirming-that-Sanofi-Pasteur-s-Vaccine-Candidate-Safely-Protects-Pre-Adolescents-to-Adults-Against-Dengue.aspx. Accessed on: 29 July 2015.